BiotechTube
NK:IO

NK:IO

London, United Kingdom· Est.
nk-io.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $10M

Overview

NK:IO is a preclinical-stage biotech developing novel NK cell and small molecule immunotherapies for cancer. The company has built three proprietary technology platforms—wNK:IO, eNK:IO, and dNK:IO—aimed at overcoming the key limitations of NK cell therapies: poor expansion and rapid exhaustion. Backed by prominent UK seed investors and founded on research from Imperial College, NK:IO is targeting hard-to-treat cancers like ovarian cancer with its enhanced and engineered NK cell approaches.

Oncology

Technology Platform

Three proprietary platforms for NK cell therapy: 1) wNK:IO for enhanced expansion of non-engineered NK cells from cord blood stem cells; 2) eNK:IO for engineered NK cells with deleted inhibitory receptors; 3) dNK:IO for small molecule REV-ERB antagonists that mobilize endogenous NK cell production in vivo.

Funding History

1
Total raised:$10M
Seed$10M

Opportunities

The large and growing market for NK cell therapies presents a significant opportunity if NK:IO can solve the key challenges of cell expansion and exhaustion.
Its unique small molecule platform (dNK:IO) offers a novel, off-the-shelf pharmacological approach to boosting innate immunity, potentially applicable beyond oncology to infectious diseases.

Risk Factors

High technical risk as all platforms are in early preclinical development, with unproven safety and efficacy in humans.
Intense competition in the rapidly advancing NK cell therapy space from better-funded entities.
Reliance on continued equity financing to reach clinical milestones.

Competitive Landscape

NK:IO competes in a crowded field of companies developing allogeneic NK cell therapies, including those using iPSC-derived cells (e.g., Fate Therapeutics), cord blood-derived cells (e.g., Nkarta, Gamida Cell), and engineered CAR-NK approaches. Its differentiation hinges on its proprietary expansion technology to prevent exhaustion and its parallel small molecule platform.

More companies in United Kingdom →